GlaxoSmithKline expanded its oligonucleotide and pulmonary portfolios with two major deals: a global license for two siRNA assets from Frontier Biotechnologies and a $950 million acquisition of 35Pharma, which includes a Phase II‑ready pulmonary hypertension candidate. GSK will pay $40 million upfront for the siRNA programs plus nearly $1 billion in milestones, and $950 million cash for 35Pharma. The Frontier siRNA programs strengthen GSK’s immunology pipeline with assets at IND and preclinical stages; the 35Pharma buy brings HS‑235, intended for pulmonary hypertension. GSK executives framed both moves as strategic bets on platform technologies and cardiopulmonary opportunities. These transactions underscore large pharma’s continuing appetite for external innovation to refill pipelines quickly, particularly in RNA therapeutics and cardiopulmonary indications where clinical demand and market potential remain robust.